Covid19, Vaccine Adverse Reaction
Conditions
Keywords
Sputnik V, Gam-COVID-Vac, Vaccine safety, Vaccine reactogenicity, Vaccine immunogenicity
Brief summary
This study will assess the safety, reactogenicity, and immunogenicity of Gam-COVID-Vac (Sputnik V) vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). The vaccine contains two recombinant adenoviral vectors harbouring SARS-CoV-2 Spike gene. The vaccine will be administered intramuscularly on a 2-dose prime-boost schedule. Participants will be healthy adults aged greater than or equal to 18 years, voluntarily undergoing vaccination according to the guidelines of the Ministry of Healthcare of Kazakhstan.
Detailed description
Sputnik V (Gam-COVID-Vac) is an adenoviral vector vaccine developed by The Gamaleya Research Institute of Epidemiology and Microbiology (Moscow, Russia), registered and approved by the Ministry of Healthcare of Kazakhstan. The vaccine incorporates two recombinant adenoviral (rAd) vectors, rAd5 and rAd26, harbouring SARS-CoV-2 Spike (S) gene. Earlier Phase I/II clinical trials established that Sputnik V is safe and efficacious when given intramuscularly in two sequential doses, as a rAd26-S prime at day 0 followed by rAd5-S boost at day 21, at 1x10\^11 particles per dose. The aim of the current study is to provide data on the safety, reactogenicity, and immunogenicity of Sputnik V in adults vaccinated in Kazakhstan using the established vaccination regimen. In addition, the effects of prior COVID-19 exposure on the vaccine safety, reactogenicity, and immunogenicity will be assessed.
Interventions
BIOLOGICALSputnik V
Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
Sponsors
McMaster University
Karaganda Medical University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participant must be healthy (in the physician's clinical judgment and as confirmed by medical records, and physical examination at screening). * Willing to give informed consent, and answer short questionnaires on past exposure to COVID-19 and post-vaccination reactogenicity. * Willing to comply with the requirements of the protocol.
Exclusion criteria
* Participant shows signs of an acute illness (excluding minor illnesses such as diarrhea or mild upper respiratory tract infection). * Participant has a positive laboratory-confirmed test result for SARS-CoV-2 infection at screening. * Deemed by investigators to be unlikely to complete study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Solicited Adverse Events (AEs) for 21 Days after First Vaccination | day 21 | Solicited AEs are pre-defined local (at the injection site) and systemic adverse events, for which participants are questioned. Solicited local AEs include injection site pain, redness, swelling, itching. Solicited systemic AEs include fatigue, headache, myalgia, chills, fever, joint pain, nausea, vomiting, diarrhea, abdominal pain, rash external to injection site. |
| Number of Participants with Solicited Adverse Events (AEs) for 42 Days after First Vaccination | day 42 | Solicited AEs are pre-defined local (at the injection site) and systemic adverse events for which participants are questioned. Solicited local AEs include injection site pain, redness, swelling, itching. Solicited systemic AEs include fatigue, headache, myalgia, chills, fever, joint pain, nausea, vomiting, diarrhea, abdominal pain, rash external to injection site. |
| Change in the Titres of Systemic SARS-CoV-2 Binding Antibodies | Up to 6 months | The titres of SARS-CoV-2 binding antibodies measured in serum/plasma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the concentration of systemic cytokines | Up to 6 months | The levels of cytokines measured in blood plasma. |
| Change in the Titres of Mucosal SARS-CoV-2 Binding Antibodies | Up to 6 months | The titres of SARS-CoV-2 binding antibodies measured in mucosal (nasal) swabs. |
| Difference in the study outcomes between participants with and without prior COVID-19 exposure. | Up to 6 months | The reactogenicity and immunogenicity readouts will be compared between participants with and without prior COVID-19 exposure, as defined by the presence of SARS-CoV-2-reactive antibodies prior to vaccination. |
| Change in the Titres of Systemic SARS-CoV-2 Neutralizing Antibodies | Up to 6 months | The titres of SARS-CoV-2 neutralizing antibodies measured in serum/plasma. |
| Change in the titres of Mucosal SARS-CoV-2 Neutralizing Antibodies | Up to 6 months | The titres of SARS-CoV-2 neutralizing antibodies measured in mucosal (nasal) swabs. |
Countries
Kazakhstan
Outcome results
None listed